hli logo
Normal view MARC view
  • Advances in the treatment of SCLC have been slow but sure over the past decade. It is now recognized that a small subset of patients may be cured of this disease, particularly with combined modality treatment with radiation therapy and systemic chemotherapy. However, perhaps only 25 of all patients will be candidates for this intensive/combined modality approach. Therefore, there is a need to identify effective combination chemotherapy regimens that can be easily administered to the remaining 75 of poor prognosis SCLC patients. Our studies and those of others would suggest that the combination of carboplatin and oral etoposide is a highly effective regimen for the treatment of these patients with results equal to and comparable with more intensive schedules. The ease of administration of this combination with acceptable toxicity would suggest that for such a subset of patients it may be the treatment of choice against which other combination schedules should be compared.

Entry Topical Term

Number of records used in: 1

001 - CONTROL NUMBER

  • control field: 35086

003 - CONTROL NUMBER IDENTIFIER

  • control field: OSt

005 - DATE AND TIME OF LATEST TRANSACTION

  • control field: 20180606132002.0

008 - FIXED-LENGTH DATA ELEMENTS

  • fixed length control field: 180606|| aca||aabn | a|a d

040 ## - CATALOGING SOURCE

  • Original cataloging agency: OSt
  • Transcribing agency: OSt

150 ## - HEADING--TOPICAL TERM

  • Topical term or geographic name entry element: Advances in the treatment of SCLC have been slow but sure over the past decade. It is now recognized that a small subset of patients may be cured of this disease, particularly with combined modality treatment with radiation therapy and systemic chemotherapy. However, perhaps only 25 of all patients will be candidates for this intensive/combined modality approach. Therefore, there is a need to identify effective combination chemotherapy regimens that can be easily administered to the remaining 75 of poor prognosis SCLC patients. Our studies and those of others would suggest that the combination of carboplatin and oral etoposide is a highly effective regimen for the treatment of these patients with results equal to and comparable with more intensive schedules. The ease of administration of this combination with acceptable toxicity would suggest that for such a subset of patients it may be the treatment of choice against which other combination schedules should be compared.

670 ## - SOURCE DATA FOUND

  • Source citation: Work cat.: (OSt)7450: Carney, Desmond. 32888, Carboplatin/etoposide combination chemotherapy in the treatment of poor prognosis patients with small cell lung cancer. , 1995